ATE216886T1 - Modulation der th1/th2 cytokinexpression durch ribavirin in aktivierten t-lymphozyten - Google Patents

Modulation der th1/th2 cytokinexpression durch ribavirin in aktivierten t-lymphozyten

Info

Publication number
ATE216886T1
ATE216886T1 AT97904765T AT97904765T ATE216886T1 AT E216886 T1 ATE216886 T1 AT E216886T1 AT 97904765 T AT97904765 T AT 97904765T AT 97904765 T AT97904765 T AT 97904765T AT E216886 T1 ATE216886 T1 AT E216886T1
Authority
AT
Austria
Prior art keywords
activated
ribavirin3
ribavirin
lymphocytes
modulation
Prior art date
Application number
AT97904765T
Other languages
English (en)
Inventor
Robert Tam
Kandsamy Ramasamy
Devron Averett
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26712784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE216886(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/590,449 external-priority patent/US5767097A/en
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Application granted granted Critical
Publication of ATE216886T1 publication Critical patent/ATE216886T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052Imidazole radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056Triazole or tetrazole radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
AT97904765T 1996-01-23 1997-01-21 Modulation der th1/th2 cytokinexpression durch ribavirin in aktivierten t-lymphozyten ATE216886T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/590,449 US5767097A (en) 1996-01-23 1996-01-23 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US3609497P 1997-01-17 1997-01-17
PCT/US1997/000600 WO1997026883A1 (en) 1996-01-23 1997-01-21 Modulation of th1/th2 cytokine expression by ribavirin® and ribavirin® analogs in activated t-lymphocytes

Publications (1)

Publication Number Publication Date
ATE216886T1 true ATE216886T1 (de) 2002-05-15

Family

ID=26712784

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97904765T ATE216886T1 (de) 1996-01-23 1997-01-21 Modulation der th1/th2 cytokinexpression durch ribavirin in aktivierten t-lymphozyten

Country Status (21)

Country Link
EP (1) EP0879056B1 (de)
KR (1) KR100298158B1 (de)
CN (1) CN1190198C (de)
AT (1) ATE216886T1 (de)
BR (1) BR9707154A (de)
CA (1) CA2246162C (de)
CZ (1) CZ293584B6 (de)
DE (1) DE69712316T2 (de)
DK (1) DK0879056T3 (de)
ES (1) ES2172764T3 (de)
HU (1) HU220105B (de)
IL (1) IL125088A0 (de)
NO (1) NO983372L (de)
NZ (1) NZ330784A (de)
PL (1) PL187439B1 (de)
PT (1) PT879056E (de)
RU (1) RU2186569C2 (de)
SI (1) SI9720013A (de)
SK (1) SK283342B6 (de)
UA (1) UA46815C2 (de)
WO (1) WO1997026883A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254911A1 (de) * 1996-10-16 2002-11-06 ICN Pharmaceuticals, Inc. Monozyklische L-Nukleoside, analoga und ihre Anwendungen
HUP9904665A3 (en) 1996-10-25 2000-11-28 Minnesota Mining And Mfg Co Sa Immune response modifier compounds for treatment of th2 mediated and related diseases
CA2357735A1 (en) * 1999-01-29 2000-08-03 Icn Pharmaceuticals, Inc. Modulation of immune response by ribavirin
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2002014362A2 (en) * 2000-08-17 2002-02-21 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
WO2003024481A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
RU2005133093A (ru) * 2003-03-28 2006-07-27 Фармассет, Инк. (Us) Соединения для лечения флавивирусных инфекций
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
EP1973608A1 (de) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunstimulatorische nukleinsäure-packteilchen zur behandlung von überempfindlichkeit
EP2051728A4 (de) * 2006-03-09 2010-03-31 Om Pharma Immunomodulatorische verbindungen und behandlung von erkrankungen infolge einer überproduktion an inflammatorischen zytokinen
CA2655108C (en) 2006-06-12 2019-05-07 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
CN104114568B (zh) 2011-12-22 2017-09-01 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PL2861611T3 (pl) 2012-05-25 2017-08-31 Janssen Sciences Ireland Uc Nukleozydy uracylowe spirooksetanu
EA201590943A1 (ru) 2012-12-21 2016-01-29 Алиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
CN113712989A (zh) 2013-10-11 2021-11-30 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
MX2016014761A (es) 2014-05-16 2017-05-25 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2109528A1 (en) * 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases

Also Published As

Publication number Publication date
AU700642B2 (en) 1999-01-14
SI9720013A (sl) 1999-06-30
DE69712316D1 (en) 2002-06-06
WO1997026883A1 (en) 1997-07-31
EP0879056B1 (de) 2002-05-02
ES2172764T3 (es) 2002-10-01
DE69712316T2 (de) 2003-01-02
NO983372L (no) 1998-09-21
UA46815C2 (uk) 2002-06-17
HUP9900681A2 (hu) 1999-07-28
KR19990081930A (ko) 1999-11-15
HU220105B (hu) 2001-10-28
CZ293584B6 (cs) 2004-06-16
PL328003A1 (en) 1999-01-04
SK283342B6 (sk) 2003-06-03
EP0879056A1 (de) 1998-11-25
RU2186569C2 (ru) 2002-08-10
NO983372D0 (no) 1998-07-22
HUP9900681A3 (en) 1999-12-28
DK0879056T3 (da) 2002-08-19
CN1209747A (zh) 1999-03-03
IL125088A0 (en) 1999-01-26
AU1747897A (en) 1997-08-20
BR9707154A (pt) 1999-05-25
PL187439B1 (pl) 2004-07-30
KR100298158B1 (ko) 2001-09-06
CN1190198C (zh) 2005-02-23
EP0879056A4 (de) 1999-01-13
SK100498A3 (en) 2001-03-12
CA2246162C (en) 2000-04-04
CZ232998A3 (cs) 1999-04-14
NZ330784A (en) 1999-02-25
PT879056E (pt) 2002-10-31
CA2246162A1 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
ATE216886T1 (de) Modulation der th1/th2 cytokinexpression durch ribavirin in aktivierten t-lymphozyten
PT79182A (de) Mittel zur transdermalen applikation von arzneimittelwirkstoffen
EP0219076A3 (en) Sustained release composition
BR9712527A (pt) L-nucleosìdeos monocìclicos, análogos e seus empregos
DE3682457D1 (de) Geraet zur verabreichung von medikamenten an patienten.
DE59007178D1 (de) Verwendung alkylierter Polyethylenimine als gallensäureadsorbierende Arzneimittel sowie pharmazeutische Präparate.
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
DE3677897D1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
ES2056854T3 (es) Tiadiazinonas.
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
EP1240899A3 (de) Regulierung der TH1/TH2 Cytokinexpression durch Ribavirin and Ribavirinanaloge in activierten T-Lymphocyten, zur Behandlung der HCV-Infektionen
IT8548055A1 (it) Composizioni farmaceutiche per la terapia di sindromi cerebrali involutive e del decadimento mentale
ATE84058T1 (de) Gel-zusammensetzung.
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
DK369886A (da) Hidtil ukendte acylphosphotriamider og pharmaceutisk komposition indeholdende samme til aendring af lipidindholdet i blodplasma hospattedyr
ATE87207T1 (de) Azapropazon zur praevention von post-ischaemischem gewebeschaden.
EP1174141A3 (de) Regulierung der TH1/TH2 Cytokinexpression durch Ribavirin and Ribavirinanaloge in activierten T-Lymphocyten
KR890001549A (ko) 위염 치료제

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
RZN Patent revoked